Myelodysplastic syndromes can be effectively treated with lenalidomide
This article has no abstract so we have provided the first paragraph of the full text.
Lenalidomide is approved in the US for the treatment of transfusion-dependent anemia in patients who have low-risk or intermediate-1-risk myelodysplastic syndromes (MDS) with a chromosome 5q interstitial deletion. A multicenter phase II study has now shown that lenalidomide is effective in treating patients who have MDS with normal karyotypes or cytogenetic abnormalities other than 5q deletion.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.